Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL

In this study, efficacy and safety of 2 regimens that combine the CD3-CD20 T cell engager epcoritamab with venetoclax will be tested in relapsed/refractory CLL and SLL patients. The trial starts with phase I part to establish the recommended dose level (RDL) of epcoritamab in the combination with venetoclax for the phase II trial.

Trial Details

NCT ID
NCT05791409
Phase
PHASE1 / PHASE2
Sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Epcoritamab
  • Venetoclax
Locations (sample)
  • Melbourne, Australia|-37.814,144.96332
  • Melbourne, Australia|-37.814,144.96332
  • Melbourne, Australia|-37.814,144.96332
  • Antwerp, Belgium|51.22047,4.40026
  • Roeselare, Belgium|50.94653,3.12269

Key Eligibility Criteria

  • Documented relapsed or refractory CLL or SLL (SLL in phase II part only) following at least one systemic 1st-line treatment
  • Requiring treatment according to IWCLL criteria (appendix A);
  • Age at least 18 years;
  • ECOG/WHO performance status 0-2;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →